According to this paper, men receiving up to four years’ treatment of 5α-reductase inhibitors for lower urinary tract symptoms showed no evidence of an increased risk of prostate cancer with Gleason scores 8-10.
Latest research
Published 18 June 2013
Published 19 June 2013
Published 13 June 2013
Published 11 June 2013
Published 30 May 2013
Published 28 May 2013
Published 24 May 2013
Published 23 May 2013
THIS WEEK'S POLL
Research news
18 June 2013
18 June 2013
Minerva
19 June 2013
12 June 2013
12 June 2013
5 June 2013
Published 18 June 2013
Published 18 June 2013
Published 18 June 2013
Published 6 June 2013









